Cargando…

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals

BACKGROUND: Plasma-derived β-amyloid, tau, and neurodegeneration (ATN) biomarkers can accurately diagnose Alzheimer’s disease (AD) and predict its progression. Few studies have investigated the relationship between plasma biomarkers and changes in plasma inflammatory markers in clinically diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Qingling, Ni, Jingnian, Wei, Mingqing, Long, Siwei, Li, Ting, Fan, Dongsheng, Lu, Tao, Shi, Jing, Tian, Jinzhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433929/ https://www.ncbi.nlm.nih.gov/pubmed/36062146 http://dx.doi.org/10.3389/fnagi.2022.963845

Ejemplares similares

A new age-related cutoff of medial temporal atrophy scale on MRI improving the diagnostic accuracy of neurodegeneration due to Alzheimer’s disease in a Chinese population
por: Wei, Mingqing, et al.
Publicado: (2019)

Plasma repressor element 1-silencing transcription factor levels are decreased in patients with Alzheimer's disease
por: Wei, Mingqing, et al.
Publicado: (2022)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuchen, et al.
Publicado: (2023)

Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer’s disease: a retrospective analysis
por: Shi, Jing, et al.
Publicado: (2017)

Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
por: Iaccarino, Leonardo, et al.
Publicado: (2017)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia
por: Vipin, Ashwati, et al.
Publicado: (2022)

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study
por: Wang, Yan-Li, et al.
Publicado: (2021)

The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: a study protocol for a randomized controlled trial
por: Tian, Jinzhou, et al.
Publicado: (2016)

Efficacy and safety of Tianmabianchunzhigan in mild to moderate vascular dementia: Protocol of a randomized controlled IIa trial
por: Tian, Jinzhou, et al.
Publicado: (2018)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Herbal formula GAPT prevents beta amyloid deposition induced Ca(2+)/Calmodulin-dependent protein kinase II and Ca(2+)/Calmodulin-dependent protein phosphatase 2B imbalance in APPV717I mice
por: Shi, Jing, et al.
Publicado: (2016)

Retraction Note: Herbal formula GAPT prevents beta amyloid deposition induced Ca(2+)/Calmodulin-dependent protein kinase II and Ca(2+)/Calmodulin-dependent protein phosphatase 2B imbalance in APPV717I mice
por: Shi, Jing, et al.
Publicado: (2021)

The Chinese version of story recall: a useful screening tool for mild cognitive impairment and Alzheimer’s disease in the elderly
por: Shi, Jing, et al.
Publicado: (2014)

Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China
por: Jiao, Bin, et al.
Publicado: (2021)

The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease
por: Sato, Naoyuki, et al.
Publicado: (2015)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

The Pattern Element Scale: A Brief Tool of Traditional Medical Subtyping for Dementia
por: Shi, Jing, et al.
Publicado: (2013)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer’s Disease
por: Pluta, Ryszard, et al.
Publicado: (2021)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
por: Lamontagne-Kam, Daniel, et al.
Publicado: (2023)

Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology
por: Tanabe, Sean, et al.
Publicado: (2020)

Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
por: Cheng, Yuan, et al.
Publicado: (2022)

The utility of the Hopkins Verbal Learning Test (Chinese version) for screening dementia and mild cognitive impairment in a Chinese population
por: Shi, Jing, et al.
Publicado: (2012)

Increased substantia nigra echogenicity correlated with visual hallucinations in Parkinson’s disease: a Chinese population-based study
por: Li, Ting, et al.
Publicado: (2019)

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
por: Delmotte, Koen, et al.
Publicado: (2021)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
por: Chen, Jingshan, et al.
Publicado: (2023)

Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia
por: Ho, Yuen-Shan, et al.
Publicado: (2011)

Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review
por: Teng, Yuou, et al.
Publicado: (2022)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

The Potential of LPS-Binding Protein to Reverse Amyloid Formation in Plasma Fibrin of Individuals With Alzheimer-Type Dementia
por: Pretorius, Etheresia, et al.
Publicado: (2018)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
por: McCollum, Lauren E., et al.
Publicado: (2021)

Mechanism of neurodegeneration through tau and therapy for Alzheimer's disease
por: Takashima, Akihiko
Publicado: (2016)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration
por: Gijs, Marlies, et al.
Publicado: (2021)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nef69rrnr53mtsf80i5gagvhos